Preston C. Sprenkle, MD
Biography
Research & Publications
Patient Care
News
Locations
Appointments
Biography
Dr. Preston C. Sprenkle specializes in the treatment of urologic cancers, including prostate cancer, kidney cancer, bladder cancer, testicular cancer and sarcoma – a rare kind of cancer that grows in cells that connect or support other parts of the body, like bone or muscle.
Dr. Sprenkle has dedicated his career to using the latest imaging technologies to improve diagnosis. He was one of the first physicians nationwide to implement the use of the Artemis Device. This machine, introduced in 2009, allows a surgeon to use 3D ultrasound technology and merge it with even more precise magnetic resonance imaging (MRI) to accurately identify cancerous tumors.
“Skilled and experienced radiologists are rare for this relatively new technique,” Dr. Sprenkle explains. “At Yale, we are fortunate to have some of the world leaders in prostate MRI.”
Dr. Sprenkle is also a pioneer in “focal therapy,” which allows a surgeon to treat tiny prostate lesions, rather than the whole organ. This avoids many of the side effects—such as erectile dysfunction and incontinence—that may follow the removal of the whole prostate.
“Exciting technological advances are revolutionizing urology. Prostate cancer is very common and current treatments can majorly impact a man's sexual and urinary function,” Dr. Sprenkle says. “Developing ways to minimize the impact of prostate cancer diagnosis and treatment on a man's health and quality of life is tremendously rewarding.”
Dr. Sprenkle believes in working with patients to come up with individualized treatment plans. “I want my patients to feel that I hear their concerns and treat them like a person. I am pleased at the end of a long consultation when they feel like they understand their disease and their options.”
Education & Training
- Non Degree ProgramYale School of Management, Emerging Leaders Program (2018)
- FellowshipMemorial Sloan Kettering Cancer Center (2011)
- ResidencyNew York Presbyterian Hospital (2009)
- InternshipNew York Presbyterian Hospital (2005)
- MDColumbia University (2004)
- BAStanford University, Human Biology (1998)
Activities
- TULSA Pro for prostate cancer discussionParticipated in virtual support group for men with prostate cancer on the East Coast of the United States 2022Discussed new novel treatment, TULSA Pro ablation, for prostate cancer patients with men on the ZERO Men Fighting Cancer prostate cancer support group.
- ASCO GU 2022: Key Takeaways in Prostate Cancer Imaginghttps://www.docwirenews.com/round-the-wire-gu/ 2022Oncology Now Roundtable with other Urologic Oncology experts on PSMA-based diagnostic imaging and treatments.
- Prostate cancer outcomes, comparing surgery and radiation. Side effects of robotic prostatectomyAIS Channel Live Surgery 2022
- Negative Prostate MRIVienna, Austria 2021Negative MRI is associated with very low rates of detecting prostate cancer, but is often not adequate on its own to rule out disease.
- NCCN Early Detection of Prostate Cancer Guidelines UpdateBoston, United States 2021
- SymposiumPresentations available online through AUA 2021 2021Symposium Discussing use of PSMA-based imaging for prostatte cancer
- How to: Prostate UltrasoundCreated instructional Video for AUA Educational Series 2021
- How To: Placement of Endorectal Spacer and Fiducial MarkersCreated instructional Video for AUA Educational Series 2021
- Negative prostate MRI, can prostate biopsy be avoided?Vienna, Austria 2021
- Diagnostic Test for Early Detection of Prostate Cancer, review of NCCN Guidelines updateFourth Global Summit on Precision Diagnosis for Prostate Cancer 2020
- Diagnostic Tests for Early Detection of Prostate Cancer, review of NCCN guidelines updatesBoston, United States 2019
- Integrating a rectal spacer procedure into urology practiceChicago, United States 2019
- Prostate Cancer Session ModeratorProvidence, United States 2019
- Multimodal treatment of advanced prostate cancer, discussion panel memberProvidence, United States 2019
- Diagnostic Tests for Early Detection of Prostate Cancer, review of NCCN guidelines updatesBoston, United States 2018
- Hands On Training Course, MR-US fusion prostate biopsy tips and tricksSan Francisco, United States 2018
- Session Moderator: Prostate cancer genomics panelHartford, United States 2018
- Diagnostic Tests for Early Detection of Prostate Cancer, review of NCCN guidelines updatesBoston, United States 2017
- MR-US Fusion Biopsy, West Haven VA experienceBoston, United States 2017
- Principles of Image RegistrationLinthicum Heights, United States 2017
- MR-US fusion biopsy in practice: Yale University experienceLinthicum Heights, United States 2017
- Yale experience with SpaceOAR rectal spacerMontreal, Canada 2017
- Outcomes of Serial MRI-Fusion Biopsy in Men with Prostate Cancer Managed with Active SurveillanceBoston, United States 2017
- Physician learning curve using MR-US fusion prostate biopsyMontreal, Canada 2017
- Image Registration in MR-US Fusion biopsyChicago, United States 2016
- Focal ablation for prostate cancerPortland, United States 2016
- Should we still biopsy patients with a negative MP-MRI?San Diego, United States 2016
- Emerging role of MR-US fusion prostate biopsyHartford, United States 2015
- MR-US Fusion prostate biopsy: improving prostate cancer diagnosisWest Haven, United States 2015
- Prostate Cancer ScreeningWest Haven, United States 2015
- MRI targeted biopsy alone is inadequate to detect clinically significant prostate cancer: a meta-analysis.Nassau, Bahamas 2015
- MRI-Fusion biopsy in a firt-time biopsy cohort yields increased detection of clinically significant cancer using a simplified MRI grading scale.Orlando, United States 2015
- MRI-US fusion prostate biopsy, improving cancer detectionProvidence, United States 2014
- Urine Neutrophil Gelatinase-Associated Lipocalin (uNGAL) as a marker for Acute Kidney Injury in Kidney Surgery PatientsBethesda, United States 2012
- Grand Round Presentation "Management of T1 Bladder Cancer"Brooklyn, United States 2011
- Annual Meeting, Society of Urologic Oncology "B7x is a seum marker for prostate cancer."Bethseda, United States 2009
- B7x is a serum marker for prostate cancerBethesda, United States 2009
- Annual Meeting, American Urological Association, "The bladder trigone is not a Wolffian duct remnant."San Francisco, United States 2006
- The bladder trigone is not a Wolffian duct remnantSan Francisco, United States 2006
Honors & Recognition
Award | Awarding Organization | Date |
---|---|---|
2021 Thesis Reviewer, PA Master Thesis Committee, Yale School of Medicine | 2021 | |
Mentor Appreciation Award | Interprofessional Longitudinal Clinical Experience | 2017, 2018, 2019, 2020 |
Best Poster Podium Presentation | Young Urologic Oncologist dinner, Society Of Urologic Oncology Annual Meeting | 2009 |
Finalist - NY section AUA Valentine Essay Contest | NY Academy of Medicine | 2009 |
Finalist - NY section AUA Valentine Essay Contest | NY Academy of Medicine | 2007 |
First Prize - NY section AUA Valentine Essay Contest | NY Academy of Medicine | 2006 |
Arnold P. Gold Humanism in Medicine Honors Society | 2004 | |
Alpha Omega Alpha Medical School Honors Society | 2004 | |
Outstanding Member of Stanford Community | Stanford University | 1998 |
Member, Board of Directors | Stanford University Alumni Association | 1997 |
Professional Service
Organization | Role | Date |
---|---|---|
Clinical Advisory Board, Profound Medical | Board Member | 2022 - 2023 |
NCCN Prostate Cancer Early Detection Guideline Panel | Vice Chair | 2021 - Present |
Department of Urology Medical Student Thesis review committee | Member | 2021 - 2023 |
VHA National Surgery Office - Robotic Surgery Surgical Advisory Board | Member | 2021 - Present |
NIH | Ad Hoc reviewer for NIH Clinical Trials Genitourinary Steering Committee | 2019 |
Scientific Advisory Board, Boston Scientific Inc. | Scientific review and advice on urologic products | 2019 - Present |
MCIC LLC | Surgeon representative on multi-institutional meetings to improve clinical outcomes | 2018 - Present |
Department of Urology Executive Committee | Member | 2016 - Present |
Urologic Oncology | Reviewer | 2016 - Present |
Oncotarget | Reviewer | 2016 - Present |
Nature Scientific Reports | Reviewer | 2016 - Present |
Department of Urology Residency Promotion Committee | Member | 2015 - 2019 |
Yale Prostate SPORE kickoff meeting | Planning Committee | 2015 |
Frontiers | Associate Editor | 2015 - Present |
Clinical Genitourinary Cancer | Reviewer | 2015 - Present |
PLOS One | Reviewer | 2015 - Present |
Yale Interdisciplinary Prostate Program | Interdisciplinary group focused on collaborative research and development of clinical programs in prostate cancer | 2015 - Present |
Yale Urology Prostate Cancer Screening Clinic | Participant | 2015 - Present |
NCCN Prostate Cancer Early Detection Guideline Panel | Board Member | 2014 - 2021 |
Urologic Clinical Cost and Value Committee | Member | 2014 - 2016 |
Interventional Radiology Purchasing Committee | Expert Panel Member | 2014 - 2016 |
Journal of Urology | Reviewer | 2009 - Present |
Frontiers in Science | Reviewer | 2009 - Present |
Urology | Reviewer | 2009 - Present |
Society of Urologic Oncology | Member | 2009 - Present |
Washington Heights free prostate cancer education and screening clinic | Participant | 2008 |
American Association of Clinical Urologists | Member | 2006 - Present |